Author: admin

Obesity Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical trials, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight

“Obesity Treatment Market”
Obesity Companies such as Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others

(Albany, USA) DelveInsight’s “Obesity Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Obesity market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Obesity market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Obesity treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Obesity market.

 

Request for a Free Sample Report @ Obesity Market Forecast

 

Some facts of the Obesity Market Report are:

  • In March 2025, Novo Nordisk launched NovoCare® Pharmacy, a direct-to-patient delivery service, to ensure access to Wegovy® (semaglutide) injection in all dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg). This service offers uninsured patients or those with commercial insurance lacking obesity medicine coverage the option to purchase Wegovy® at a reduced cost of $499 per month. This initiative expands Novo Nordisk’s efforts to meet the needs of individuals living with obesity, following the FDA’s confirmation that the shortage of the medication has been resolved and that all doses now meet or exceed U.S. demand.
  • In February 2025, Eli Lilly launched 7.5 mg and 10 mg Zepbound (tirzepatide) vials for $499 through the Zepbound Self Pay Journey Program, alongside price reductions for 2.5 mg and 5 mg vials. These are available exclusively via LillyDirect Self Pay Pharmacy Solutions, offering direct savings outside of insurance.
  • In February 2025, Amgen announced that the U.S. FDA has placed a hold on a study of the company’s early-stage obesity candidate, AMG 513, marking another potential setback in its efforts to enter the growing weight loss drug market. Amgen has provided limited information about the drug, including its mechanism of action.
  • In January 2025, Novo Nordisk reported that a high dose of its obesity drug Wegovy led to greater weight loss than the approved regimen in a Phase III trial. However, the data also suggest that Eli Lilly’s rival GLP-1 drug Zepbound may still have an advantage over Wegovy.
  • In January 2025, Verdiva Bio Limited launched as a clinical-stage biopharmaceutical company focused on innovative therapies for obesity and cardiometabolic disorders. The company is advancing next-generation oral and injectable treatments and raised $411M in an oversubscribed Series A round, co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital.
  • In January 2025, Eli Lilly filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has ordered the Outsourcing Facilities Association to respond by January 15, with Eli Lilly’s reply due by January 21.
  • As per DelveInsight’s estimates, the United States accounted for the highest number of total prevalent cases of Obesity among the 7MM in 2023.
  • DelveInsight’s consultant estimates that adult patients constituted the maximum number of cases of obesity patients seeking help in 2023.
  • According to the findings, treatment rate for children was found to be less than that of adults across countries.
  • Among EU4 and the UK, the highest number of treated cases of obesity in adults was observed in the United Kingdom in 2023, which is followed by Germany.
  • The leading Obesity Companies such as Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others
  • Promising Obesity Therapies such as IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others.
  • On June 2023, Eli Lilly and Company (NYSE: LLY) announced the new phase 2 data from retatrutide, Lilly’s investigational molecule being studied for the treatment of obesity. At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for the efficacy estimand in participants living with obesity or overweight without diabetes, demonstrating a mean weight reduction up to 17.5% (41.2 lb. or 18.7 kg). In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% (57.8 lb. or 26.2 kg)ii at the end of the 48-week treatment duration.
  • On June 2023, Pfizer (NYSE: PFE) updated that it is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue developing its other obesity pill, the twice-daily treatment danuglipron, as it races to rival the success of other weight loss treatments.
  • On May 2023, Novo Nordisk (NYSE: NVO) announced positive results from a phase IIIa study, OASIS 1, in the global OASIS program for a once-daily oral formulation of semaglutide in obesity.

 

Obesity Overview

Obesity is a chronic condition characterized by an excessive accumulation of body fat, leading to adverse health effects and increased risk of various diseases. It is typically defined by a body mass index (BMI) of 30 or higher. Obesity results from complex interactions between genetic, environmental, socioeconomic, and behavioral factors. Sedentary lifestyles, high-calorie diets, and genetic predispositions contribute to its development. Obesity is associated with numerous health complications, including type 2 diabetes, cardiovascular disease, hypertension, certain cancers, and musculoskeletal disorders. Additionally, it can impair quality of life and increase mortality rates. Prevention and management strategies for obesity include dietary modifications, regular physical activity, behavioral therapy, medications, and in severe cases, bariatric surgery. Public health initiatives and policies aimed at promoting healthy lifestyles and reducing obesity prevalence are essential to address this global epidemic and its associated health burdens.

 

Learn more about Obesity treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market

 

Obesity Market

The Obesity market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Obesity market trends by analyzing the impact of current Obesity therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Obesity market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Obesity market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Obesity market in 7MM is expected to witness a major change in the study period 2020-2034.

 

Obesity Epidemiology

The Obesity epidemiology section provides insights into the historical and current Obesity patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Obesity market report also provides the diagnosed patient pool, trends, and assumptions.

 

Explore more about Obesity Epidemiology @ Obesity Market Dynamics

 

Obesity Drugs Uptake

This section focuses on the uptake rate of the potential Obesity drugs recently launched in the Obesity market or expected to be launched in 2020-2034. The analysis covers the Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug.

Obesity Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Obesity market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Obesity Pipeline Development Activities

The Obesity report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Obesity key players involved in developing targeted therapeutics.

 

Request for a sample report to understand more about the Obesity pipeline development activities @ Obesity Medication and Approved drugs

 

Obesity Therapeutics Assessment

Major key companies are working proactively in the Obesity Therapeutics market to develop novel therapies which will drive the Obesity treatment markets in the upcoming years are Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma and others.

 

Learn more about the emerging Obesity therapies & key companies @ Obesity Clinical Trials and Advancements

 

Obesity Report Key Insights

1. Obesity Patient Population

2. Obesity Market Size and Trends

3. Key Cross Competition in the Obesity Market

4. Obesity Market Dynamics (Key Drivers and Barriers)

5. Obesity Market Opportunities

6. Obesity Therapeutic Approaches

7. Obesity Pipeline Analysis

8. Obesity Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Obesity Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Obesity Competitive Intelligence Analysis

4. Obesity Market Overview at a Glance

5. Obesity Disease Background and Overview

6. Obesity Patient Journey

7. Obesity Epidemiology and Patient Population

8. Obesity Treatment Algorithm, Current Treatment, and Medical Practices

9. Obesity Unmet Needs

10. Key Endpoints of Obesity Treatment

11. Obesity Marketed Products

12. Obesity Emerging Therapies

13. Obesity Seven Major Market Analysis

14. Attribute Analysis

15. Obesity Market Outlook (7 major markets)

16. Obesity Access and Reimbursement Overview

17. KOL Views on the Obesity Market

18. Obesity Market Drivers

19. Obesity Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obesity Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical trials, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight

Spinal Muscular Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Treatment Market, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

“Spinal Muscular Atrophy Clinical Trials”
Spinal Muscular Atrophy companies are Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others.

(Albany, USA) “Spinal Muscular Atrophy Pipeline Insight, 2025″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market.

Spinal Muscular Atrophy pipeline constitutes 18+ key companies continuously working towards developing 20+ Spinal Muscular Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Spinal Muscular Atrophy clinical trials report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

To know more in detail about Spinal Muscular Atrophy pipeline report offerings, click here: Spinal Muscular Atrophy Clinical Trials and Pipeline

 

Some of the key takeaways from the Spinal Muscular Atrophy Pipeline Report:

  • In March 2025, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for people living with spinal muscular atrophy (SMA) who are receiving an SMN-targeted treatment. The FDA will review the application under priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2025. The FDA priority review designation conveys that the FDA has determined that if apitegromab is approved, it could offer significant improvement in the safety or effectiveness of treatment of the serious condition of SMA
  • Spinal Muscular Atrophy Companies across the globe are diligently working toward developing novel Spinal Muscular Atrophy treatment therapies with a considerable amount of success over the years.
  • Leading Spinal Muscular Atrophy companies working in the market are Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others, are developing therapies for the Spinal Muscular Atrophy treatment
  • Spinal Muscular Atrophy emerging therapies such as – ACTX-401, Apitegromab, GYM329, and others are expected to have a significant impact on the Spinal Muscular Atrophy market in the coming years.
  • In February 2025, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam) tablet for people living with spinal muscular atrophy (SMA). Evrysdi is the only non-invasive disease-modifying treatment for SMA. The 5 mg Evrysdi tablet can either be swallowed whole or dispersed in water.
  • In January 2025, Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the application for a higher dose regimen of nusinersen for spinal muscular atrophy (SMA). The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (SPINRAZA®).
  • On April 2024, Hoffmann-La Roche announced a Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene Therapy
  • On April 2024, Genentech announced results of a multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with spinal muscular atrophy (SMA). In this study, participants will be followed for up to 5 years from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study, if they agree to continue participating in the follow-up assessments.
  • On April 2024, Biogen announced results of a study whose primary objective is to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA), as measured by change in Children’s Hospital of Philadelphia-Infant Test of Neuromuscular Disorders (CHOP-INTEND) total score (Part B); to examine the safety and tolerability of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A and C).
  • On January 2024, Novartis announced results of a Phase IIIb, Open-label, Single-arm, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally (1.2 x 10^14 Vector Genomes) to Participants 2 to < 18 Years of Age With Spinal Muscular Atrophy (SMA) Who Have Discontinued Treatment With Nusinersen (Spinraza®) or Risdiplam (Evrysdi®).
  • On January 2024, NMD Pharma A/S announced results of a Phase 2, Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults With Type 3 Spinal Muscular Atrophy
  • On December 2023, Novartis announced results of a Long-term Safety Study in Brazilian Patients With a Confirmed Diagnosis of Spinal Muscular Atrophy (SMA) Treated With Onasemnogene Abeparvovec (Zolgensma®) – ARISER Study.
  • On May 2023, Biogen announced results of a study whose primary objective is to describe the natural history and utilization of disease modifying therapy (DMT) among adult Chinese participants with SMA linked to chromosome 5q (5q-SMA)

 

To know in detail about the Spinal Muscular Atrophy clinical trials and recent FDA approvals for Spinal Muscular Atrophy drugs, click here: Spinal Muscular Atrophy Drugs and Therapies

 

Spinal Muscular Atrophy Overview

Spinal Muscular Atrophy (SMA) is a rare genetic neuromuscular disorder that affects motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. It is caused by mutations in the SMN1 (Survival Motor Neuron 1) gene, which results in reduced levels of the SMN protein essential for motor neuron survival. The severity of SMA varies, and it is classified into different types (SMA 0–4) based on age of onset and disease progression.

Spinal Muscular Atrophy primarily affects voluntary muscles, particularly those involved in movement, breathing, and swallowing. Spinal Muscular Atrophy Symptoms range from severe muscle weakness in infancy (SMA Type 1, the most common and severe form) to milder symptoms with later onset (SMA Type 3 and 4). In severe cases, respiratory complications can be life-threatening.

Spinal Muscular Atrophy Diagnosis is confirmed through genetic testing. While there is no cure, disease-modifying therapies like nusinersen (Spinraza), risdiplam (Evrysdi), and gene therapy with onasemnogene abeparvovec (Zolgensma) can improve motor function and survival. Supportive care, including physical therapy, respiratory support, and nutritional management, plays a crucial role in improving the quality of life.

Spinal Muscular Atrophy Advancements in treatment and early intervention, especially through newborn screening, have significantly improved outcomes for individuals with SMA.

 

Spinal Muscular Atrophy Pipeline Therapeutics Assessment

  • Spinal Muscular Atrophy Assessment by Product Type
  • Spinal Muscular Atrophy By Stage and Product Type
  • Spinal Muscular Atrophy Assessment by Route of Administration
  • Spinal Muscular Atrophy By Stage and Route of Administration
  • Spinal Muscular Atrophy Assessment by Molecule Type
  • Spinal Muscular Atrophy by Stage and Molecule Type

 

DelveInsight’s Spinal Muscular Atrophy Report covers around 20+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Emerging Spinal Muscular Atrophy Drugs Under Different Phases of Clinical Development Include:

  • ACTX-401: Novartis
  • Apitegromab: Scholar Rock
  • GYM329: Roche
  • And Many Others

 

Get a Free Sample PDF Report to know more about Spinal Muscular Atrophy Pipeline Assessment- Spinal Muscular Atrophy Medication

 

Spinal Muscular Atrophy Pipeline Analysis:

  • The Spinal Muscular Atrophy pipeline report provides insights into
  • The report provides detailed insights about companies that are developing therapies for the Spinal Muscular Atrophy treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment.
  • Spinal Muscular Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market.
  • The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Spinal Muscular Atrophy product details are provided in the report. Download the Spinal Muscular Atrophy pipeline report to learn more about the emerging Spinal Muscular Atrophy therapies @ Spinal Muscular Atrophy Companies and Drugs

 

Scope of Spinal Muscular Atrophy Pipeline Drug Insight

  • Coverage: Global
  • Key Spinal Muscular Atrophy Companies: Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others
  • Key Spinal Muscular Atrophy Therapies: AS-202, HK001, Tegoprubart, AP-101, BLZ945, ANX005, MN-166, TW001, BIIB067, and others
  • Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies
  • Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers

 

Request for Sample Report @ Spinal Muscular Atrophy Pipeline Outlook

 

Table of Contents

  • Spinal Muscular Atrophy Report Introduction
  • Spinal Muscular Atrophy Executive Summary
  • Spinal Muscular Atrophy Overview
  • Spinal Muscular Atrophy- Analytical Perspective In-depth Commercial Assessment
  • Spinal Muscular Atrophy Pipeline Therapeutics
  • Spinal Muscular Atrophy Late Stage Products (Phase II/III)
  • Spinal Muscular Atrophy Mid Stage Products (Phase II)
  • Spinal Muscular Atrophy Early Stage Products (Phase I)
  • Spinal Muscular Atrophy Preclinical Stage Products
  • Spinal Muscular Atrophy Therapeutics Assessment
  • Spinal Muscular Atrophy Inactive Products
  • Company-University Collaborations (Licensing/Partnering) Analysis
  • Spinal Muscular Atrophy Key Companies
  • Spinal Muscular Atrophy Key Products
  • Spinal Muscular Atrophy Unmet Needs
  • Spinal Muscular Atrophy Market Drivers and Barriers
  • Spinal Muscular Atrophy Future Perspectives and Conclusion
  • Spinal Muscular Atrophy Analyst Views
  • Appendix
  • About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Spinal Muscular Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Treatment Market, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

Binge eating disorder Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Statistics, Revenue, Therapies, Treatment, Companies by DelveInsight

“Binge eating disorder Treatment Market”
Binge eating disorder companies are TRYP Therapeutics, Tonix Pharmaceuticals, Alvogen Iceland ehf, Bausch Health Companies Inc., Chronos Therapeutics Ltd., Currax Pharmaceuticals, Eli Lilly, Johnson and Johnson Services, Lupin, Omeros Corp., Pyramid Healthcare Inc., Rosewood Centers for Eating disorders, Sumitomo Pharma, Takeda Pharmaceutical, Timberline Knolls Residential Treatment Center, Tonix Pharmaceuticals, Tryp Therapeutics, Viatris, VIVUS, Walden Behavioral Care and others.

(Albany, USA) DelveInsight’s Binge Eating Disorder Market Insights report includes a comprehensive understanding of current treatment practices, binge eating disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

The Binge eating disorder market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Binge eating disorder market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Binge eating disorder treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Binge eating disorder market.

 

Request for sample report @ Binge Eating Disorder Market Insights

 

Key Takeaways from the Binge Eating Disorder Market Report

  • According to DelveInsight’s analysis, the market size for binge eating disorder is expected to grow significantly by 2034.
  • Binge eating disorder is the most common eating disorder in the United States, and it affects people of all racial and ethnic groups. About 1.25% of adult women and 0.42% of adult men have binge eating disorder.
  • Leading binge eating disorder companies such as TRYP Therapeutics, Tonix Pharmaceuticals, Alvogen Iceland ehf, Bausch Health Companies Inc., Chronos Therapeutics Ltd., Currax Pharmaceuticals LLC, Eli Lilly and Co., Johnson and Johnson Services Inc., Lupin Ltd., Omeros Corp., Pyramid Healthcare Inc., Rosewood Centers for Eating disorders, Sumitomo Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Timberline Knolls Residential Treatment Center, Tonix Pharmaceuticals Holding Corp., Tryp Therapeutics Inc., Viatris Inc., VIVUS LLC, Walden Behavioral Care and others are developing novel binge eating disorder drugs that can be available in the binge eating disorder market in the coming years.
  • The promising binge eating disorder therapies in the pipeline include TRYP-0082, TNX-1900, VYVANSE (lisdexamfetamine), among others.
  • In March 2025, Axsome Therapeutics, Inc announced an Open-Label Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Adults with Binge Eating Disorder
  • On January 30, 2025, Granules India Limited (NSE:GRAN) announced the U.S. Food & Drug Administration (FDA) approval for its generic Lisdexamfetamine Dimesylate Capsules. Available in various strengths (10 mg to 70 mg), this drug is bioequivalent to Vyvanse Capsules and is indicated for treating Attention Deficit Hyperactivity Disorder (ADHD) in both adults and children six years and older, as well as for Moderate to Severe Binge Eating Disorder (BED) in adults.
  • In January 2025, Axsome Therapeutics, Inc announced a Phase 3, Randomized, Double-blind, Placebo-Controlled Trial of Solriamfetol in Adults With Binge Eating Disorder (BED)

 

Discover which therapies are expected to grab the major binge eating disorder market share @ Binge Eating Disorder Market Report

 

Binge Eating Disorder Overview

Binge eating disorder is a serious mental health condition characterized by recurrent episodes of consuming large quantities of food in a short period while feeling a loss of control over eating behavior. Unlike bulimia nervosa, individuals with binge eating disorder typically do not engage in compensatory behaviors such as purging or excessive exercise to counteract the binge eating episodes. Several factors contribute to the development of binge eating disorder, including genetic predisposition, psychological factors like stress or low self-esteem, and environmental influences such as societal pressure to attain certain body ideals. Traumatic life events, childhood experiences, and dysfunctional family dynamics may also play a role in its onset.

Symptoms of binge eating disorder include eating unusually large amounts of food in a specific time frame, eating rapidly until feeling uncomfortably full, eating alone due to embarrassment over food intake, and experiencing feelings of guilt, shame, or distress after binge eating episodes. Individuals with BED often struggle with emotional regulation and may use food as a coping mechanism to deal with stress, anxiety, or depression. Diagnosing binge eating disorder involves a comprehensive assessment by a healthcare professional, including a physical examination, psychological evaluation, and discussion of eating habits and behaviors. Criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) are used to determine if someone meets the diagnostic criteria for BED.

Binge Eating Disorder Epidemiology Segmentation

The binge eating disorder epidemiology section provides insights into the historical and current binge eating disorder patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The binge eating disorder market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalent Cases of Binge Eating Disorder
  • Total Diagnosed Prevalent Cases of Binge Eating Disorder
  • Gender-specific Diagnosed Prevalent Cases of Binge Eating Disorder
  • Treatable Cases of Binge Eating Disorder

 

Binge Eating Disorder Treatment Market

Treatment for binge eating disorder is centered around tackling the intricate issues linked with repeated episodes of overeating, often marked by a feeling of being unable to control one’s eating habits. Therapeutic strategies, like cognitive-behavioral therapy (CBT) or dialectical behavior therapy (DBT), are commonly utilized to address the underlying emotional and psychological aspects. Additionally, nutritional guidance and encouragement are offered to encourage healthier eating habits, while medication, such as selective serotonin reuptake inhibitors (SSRIs), may be prescribed in certain instances. The primary objective is to assist individuals in managing their binge eating tendencies, enhancing their emotional state, and establishing sustainable lifestyle adjustments to facilitate long-lasting recovery.

Vyvanse (lisdexamfetamine) is the only medication approved by the FDA specifically for addressing binge eating disorders. Operating as a precursor to amphetamine, Vyvanse boosts neurotransmitter levels such as dopamine and norepinephrine in the brain, affecting impulse control and appetite management. Clinical studies have validated its effectiveness in diminishing binge eating occurrences and ameliorating associated psychological symptoms. Nonetheless, Vyvanse carries potential side effects like sleeplessness, heightened heart rate, and anxiety. Its prescription is typically reserved for situations where psychotherapy alone might not suffice, underscoring the importance of a holistic approach to treating binge eating disorder that integrates both pharmaceutical and therapeutic measures.

Fluoxetine, categorized as a selective serotonin reuptake inhibitor (SSRI), isn’t directly endorsed by the FDA for treating binge eating disorders, yet it has demonstrated effectiveness in certain instances. Despite not being formally approved for this purpose, fluoxetine is sometimes prescribed off-label to tackle the emotional and psychological aspects linked with binge eating. Through elevating serotonin levels in the brain, fluoxetine potentially aids in mood regulation and diminishing the occurrence of binge eating episodes. However, its efficacy can differ from person to person.

 

To know more about binge eating disorder treatment guidelines, visit @ Binge Eating Disorder Management

 

Binge Eating Disorder Pipeline Therapies and Key Companies

Some of the drugs in the pipeline include TRYP-0082 (TRYP Therapeutics), and TNX-1900 (Tonix Pharmaceuticals), among others.

Psilocybin (TRP-8802) signifies a groundbreaking advancement in pharmaceuticals, being developed to address various conditions such as fibromyalgia, binge eating disorder, irritable bowel syndrome (IBS), hypothalamic obesity, and chronic pain. It is administered orally in capsule form and intravenously, drawing attention to its potential to tackle a wide range of medical issues. The oral method offers convenient dosing for patients, while the intravenous route ensures precise and rapid therapeutic effects. With its unique psychedelic properties, Psilocybin presents a novel approach to treating historically difficult-to-manage disorders. Currently, the drug is undergoing Phase II clinical trials for further evaluation.

Tonix Pharmaceuticals is progressing with the development of TNX-1900, a nasal oxytocin compound enhanced for effectiveness. This medication is aimed at treating chronic migraine and binge eating disorders associated with obesity. Acquired from Trigemina, Inc., and licensed from Stanford University in 2020, the formula includes magnesium to boost oxytocin’s interaction with its receptors. Having received FDA Investigational New Drug (IND) clearance in the fourth quarter of 2021, Tonix initiated a Phase II clinical trial for BED in partnership with Massachusetts General Hospital. This trial began in March 2022 and is expected to wrap up by April 2024. It’s worth noting that Tonix Pharmaceuticals does not possess an IND for BED. Currently, the drug is undergoing Phase IIA trials for binge eating disorder treatment.

The anticipated launch of these emerging therapies for binge eating disorder are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the binge eating disorder market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

 

Learn more about the FDA-approved drugs for binge eating disorder @ Drugs for Binge Eating Disorder Treatment

 

Binge Eating Disorder Market Dynamics

The dynamics of the binge eating disorder market are expected to change in the coming years. As societal understanding evolves, coupled with advances in research and healthcare, there’s a notable shift towards integrated approaches that encompass pharmacological interventions, psychotherapy, and lifestyle modifications. Pharmaceutical companies are responding with innovative drug therapies tailored to address the underlying neurobiological mechanisms of binge eating disorder, while mental health professionals are emphasizing the importance of holistic treatment models to address both physical and psychological aspects. Moreover, the rise of telemedicine and digital health platforms is expanding access to care, allowing individuals to seek support and guidance conveniently.

Furthermore, many potential therapies are being investigated for the treatment of binge eating disorder, and it is safe to predict that the treatment space will significantly impact the binge eating disorder market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the binge eating disorder market in the 7MM.

However several factors may impede the growth of the binge eating disorder market. One prominent barrier is the stigma surrounding mental health issues, including misconceptions about binge eating disorder as a lack of willpower rather than a complex psychological disorder. This stigma can prevent individuals from seeking help or disclosing their struggles, leading to underdiagnosis and undertreatment. Additionally, limited awareness among healthcare providers and the general public about binge eating disorder as a distinct disorder further exacerbates these challenges. Furthermore, access to specialized treatment options and binge eating disorder trained in managing binge eating disorders remains limited in many regions, hindering timely intervention and support for affected individuals.

Moreover, binge eating disorder treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the binge eating disorder market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the binge eating disorder market growth.

 

Scope of the Binge Eating Disorder Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
  • Key Binge Eating Disorder Companies: TRYP Therapeutics, Tonix Pharmaceuticals, and others
  • Key Pipeline Binge Eating Disorder Therapies: TRYP-0082, TNX-1900, and others
  • Therapeutic Assessment: Binge Eating Disorder current marketed and emerging therapies
  • Binge Eating Disorder Market Dynamics: Key Market Forecast Assumptions of Emerging Binge Eating Disorder Drugs and Market Outlook
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Binge Eating Disorder Market Access and Reimbursement

 

Discover more about binge eating disorder drugs in development @ Binge Eating Disorder Clinical Trials

 

Table of Contents

1. Binge Eating Disorder Key Insights

2. Binge Eating Disorder Report Introduction

3. Binge Eating Disorder Overview at a Glance

4. Binge Eating Disorder Executive Summary

5 Binge Eating Disorder Key Events

6 Epidemiology and Market Forecast Methodology

6. Disease Background and Overview

7. Binge Eating Disorder Treatment and Management

8. Binge Eating Disorder Guidelines

9. Binge Eating Disorder Epidemiology and Patient Population

10. Patient Journey

11. Key Endpoints in Binge Eating Disorder

12. Binge Eating Disorder Marketed Drugs

13. Binge Eating Disorder Emerging Drugs

14. 7MM Binge Eating Disorder Market Analysis

15. Market Access and Reimbursement

16. KOL Views

17. Unmet Needs

18. SWOT Analysis

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Binge eating disorder Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Statistics, Revenue, Therapies, Treatment, Companies by DelveInsight

Urban Tree Enhances Safety and Storm Preparedness with Expanded Tree Services in Maple Grove

Urban Tree Enhances Safety and Storm Preparedness with Expanded Tree Services in Maple Grove
Urban Tree has expanded its professional tree care services in Maple Grove, addressing increasing concerns about storm damage, property safety, and tree maintenance. The company’s enhanced capabilities provide crucial solutions for homeowners and businesses facing tree-related hazards.

Maple Grove, MN – March 27, 2025 – The demand for expert Tree Removal Service Maple Grove has grown due to aging trees, storm damage, and disease. Urban Tree’s trained specialists use advanced techniques to safely and efficiently remove trees that risk structures and landscapes.

Severe weather events have underscored the importance of rapid Emergency Tree Removal Maple Grove services. Fallen and unstable trees can cause significant damage and safety hazards, requiring immediate professional intervention. Urban Tree’s quick response team is equipped to handle urgent situations, mitigating risks and preventing further property loss.

Routine tree maintenance is also essential for long-term property care. The company’s Tree Cutting Service Maple Grove supports healthy tree growth, improves aesthetics and reduces the likelihood of falling branches. Proper pruning and trimming can extend the life of trees while enhancing overall landscape safety.

Urban Tree’s commitment to safety, efficiency, and environmental responsibility ensures that Maple Grove residents have access to expert tree care solutions. By combining industry-leading equipment with certified expertise, the company continues to contribute to the health and safety of the local community.

Media Contact
Company Name: Urban Tree
Contact Person: Gabe Tschida
Email: Send Email
Phone: (612) 532-9996
Address:11000 93rd Ave N
City: Maple Grove
State: MN 55369
Country: United States
Website: https://utrees.com/

Peterson Painting Expands Services to Elevate Homes in Windsor Heights

Peterson Painting Expands Services to Elevate Homes in Windsor Heights
Homeowners in Windsor Heights seeking high-quality painting services now have an enhanced option as Peterson Painting announces expanded offerings to transform both interior and exterior spaces. Known for its expertise and commitment to excellence, the company continues to set the standard for professional painting in the region.

With a reputation built on precision and customer satisfaction, Peterson Painting provides tailored solutions for residential projects. Whether revitalizing interior walls or upgrading exterior surfaces, the company focuses on durability, aesthetics, and expert craftsmanship. A growing demand for skilled interior house painters Windsor Heights has driven the company to expand its team, ensuring efficient project completion without compromising quality.

Beyond walls and exteriors, Peterson Painting also specializes in cabinet refinishing, offering homeowners an alternative to costly replacements. Through a meticulous process of preparation, priming, and finishing, the company delivers flawless results for painting wood cabinets Windsor Heights residents trust. This service is ideal for those looking to refresh their kitchen or bathroom cabinetry with a modern, long-lasting finish. Additionally, using high-quality paints and sealants ensures enhanced durability, protecting cabinets from everyday wear and tear.

Curb appeal remains a top priority for many homeowners, and Peterson Painting’s expert exterior painters Windsor Heights are prepared to handle a variety of surfaces, from siding to trim and doors. Using premium materials and techniques designed to withstand the elements, the company ensures a polished, weather-resistant finish that enhances any property’s appearance. Their expertise extends to color consultations, helping homeowners choose shades that complement their architectural style while increasing home value.

Peterson Painting remains committed to providing high-quality, professional service backed by years of industry experience. Now, homeowners in Windsor Heights can access a broader range of expert painting solutions, whether inside or out.

For more information about Peterson Painting’s services or to schedule a consultation, visit their website or contact their team today.

Media Contact
Company Name: Peterson Painting
Contact Person: Cary Peterson
Email: Send Email
Phone: (515) 274-1883
Address:2110 63rd St
City: Windsor Heights
State: IA 50324
Country: United States
Website: http://www.petersonpainting.net/

Independent R&B Artist Queen Asharah Charts on Apple iTunes Canada Top 50

Queen Asharah’s single ‘811’ ranks #40 on Apple iTunes R&B Chart, marking significant indie achievement.

Independent R&B singer-songwriter Queen Asharah has reached a notable milestone with her latest single, “811,” charting at number 40 on the Apple iTunes R&B Top 50 in Canada. This achievement underscores the growing presence and impact independent artists can have in today’s music industry, traditionally dominated by major labels.

Queen Asharah, also known as Asharah Damore, exemplifies the essence of independence and creative expression. Her multi-dimensional career spans music, poetry, acting, international modeling, and a tenure as a pageant queen. Through her Omni-media brand, Asharah Unlimited, she actively engages audiences with compelling content across music, publishing, broadcast media, television, and film—particularly catering to women and families.

The chart success of “811” is particularly significant as it demonstrates that independent artists can effectively compete on prominent industry platforms. Asharah’s music blends soulful rhythms with relatable storytelling, connecting deeply with listeners. Her achievement is a testament to her commitment, talent, and the innovative approach she adopts to reach her audience.

Staying grounded yet perpetually inspired, Queen Asharah continuously challenges herself creatively, evolving her art forms to remain authentic and relevant. Her success on the Apple iTunes charts is not just a personal victory but a beacon for aspiring independent musicians who seek validation that major success can be achieved without traditional record-label support.

Expressing gratitude for this significant achievement, Queen Asharah stated, “Seeing ‘811’ chart independently reaffirms my belief in the power of authentic storytelling and connection with listeners. This milestone highlights that independent artists, with determination and passion, can thrive and succeed at the highest levels.”

Through music and beyond Queen Asharah continues to expand her artistic and entrepreneurial endeavors, emphasizing empowerment, inspiration, and family-friendly entertainment.

For the latest from Queen Asharah visit www.queenasharah.com.

Media Contact
Company Name: Queen Asharah
Email: Send Email
Phone: 678-661-7866
Country: United States
Website: www.queenasharah.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Independent R&B Artist Queen Asharah Charts on Apple iTunes Canada Top 50

Crohn’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Crohn’s Disease Pipeline Insight 2025” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn’s Disease pipeline landscape. It covers the Crohn’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Crohn’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Crohn’s Disease Treatment Landscape. Click here to read more @ Crohn’s Disease Pipeline Outlook

Key Takeaways from the Crohn’s Disease Pipeline Report

  • In March 2025, Janssen-Cilag Ltd. announced a study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn’s disease and to assess the overall safety of guselkumab.
  • In March 2025, Hoffmann-La Roche conducted a phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RO7790121 (RVT-3101) in adult participants with moderate to severe active Crohn’s disease.
  • In March 2025, AbbVie organized a study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD.
  • In January 2025:- Janssen-Cilag Ltd.:- A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants With Fistulizing, Perianal Crohn’s Disease. The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn’s disease and to assess the overall safety of guselkumab.
  • In January 2025:- Tr1X Inc.:- A Phase 1/2a, Open Label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX103 in Subjects with Moderate to Severe Treatment-Refractory Crohn’s Disease. This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn’s Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.
  • In Janssen Pharmaceutical K.K.:– A Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants With Moderately to Severely Active Crohn’s Disease. The purpose of this study is to evaluate the safety of Guselkumab in participants with Crohn’s disease.
  • In January 2025:- AbbVie:- Crohn’s disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time. This study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD.
  • DelveInsight’s Crohn’s Disease pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Crohn’s Disease treatment.
  • The leading Crohn’s Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, AbbVie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Provention Bio, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Protagonist Therapeutics, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Fast Forward Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Active Biotech, Celularity, Cerecor, GlaxoSmithKline, Kang Stem Biotech, Alpha Cancer Technologies, Koutif Therapeutics, Winston Pharmaceuticals, Tract Therapeutics, Trio Medicines, Tetherex Pharmaceuticals, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, Innovimmune Biotherapeutics, JHL Biotech, Intract Pharma Ltd, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, PlantPraxis, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Atlantic Bio Sci, Assembly Biosciences, Artelo Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo and others.
  • Promising Crohn’s Disease Pipeline Therapies such as Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13, and others.

Discover groundbreaking developments in Crohn’s Disease therapies! Gain in-depth knowledge of key Crohn’s Disease clinical trials, emerging drugs, and market opportunities @ Crohn’s Disease Clinical Trials Assessment

Crohn’s Disease Emerging Drugs Profile

  • Guselkumab: Janssen

Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. It is currently in Phase III of clinical trial.

  • RHB-104: RedHill Biopharma

RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. It is currently in Phase III of clinical trial.

The Crohn’s Disease Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Crohn’s Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn’s Disease Treatment.
  • Crohn’s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Crohn’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn’s Disease market

Stay informed about the Crohn’s Disease pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Crohn’s Disease Unmet Needs

Crohn’s Disease Companies

Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, and others.

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Crohn’s Disease Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Transform your understanding of the Crohn’s Disease Pipeline! See the latest progress in drug development and clinical research @ Crohn’s Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Crohn’s Disease Pipeline Report

  • Coverage- Global
  • Crohn’s Disease Companies- Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, and others.
  • Crohn’s Disease Pipeline Therapies- Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13, and others.
  • Crohn’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Crohn’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

“Stay Ahead in Gastroenterology Research–Access the Full Crohn’s Disease Pipeline Analysis Today! @ Crohn’s Disease Drugs and Companies

Table of Content

  1. Introduction
  2. Crohn’s Disease Executive Summary
  3. Crohn’s Disease: Overview
  4. Crohn’s Disease Pipeline Therapeutics
  5. Crohn’s Disease Therapeutic Assessment
  6. Crohn’s Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Ozanimod: Bristol-Myers Squibb
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CBP-307: Suzhou Connect Biopharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. IMU-856: Immunic
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Crohn’s Disease Key Companies
  21. Crohn’s Disease Key Products
  22. Crohn’s Disease- Unmet Needs
  23. Crohn’s Disease- Market Drivers and Barriers
  24. Crohn’s Disease- Future Perspectives and Conclusion
  25. Crohn’s Disease Analyst Views
  26. Crohn’s Disease Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Crohn’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Dementia Associated With Alzheimer’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Dementia Associated With Alzheimer’s Disease Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Dementia Associated With Alzheimer’s Disease pipeline landscape. It covers the Dementia Associated With Alzheimer’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dementia Associated With Alzheimer’s Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Dementia Associated With Alzheimer’s Disease Research. Learn more about our innovative pipeline today! @ Dementia Associated With Alzheimer’s Disease Pipeline Outlook

Key Takeaways from the Dementia Associated With Alzheimer’s Disease Pipeline Report

  • In March 2025, Karuna Therapeutics announced a phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer’s Disease (AD) with moderate to severe psychosis related to AD.
  • In March 2025, BioXcel Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has closed the inspection of a single site in its TRANQUILITY II Phase 3 trial under 21 C.F.R.20.64(d)(3) and released the Establishment Inspection Report.
  • DelveInsight’s Dementia Associated With Alzheimer’s Disease pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Dementia Associated With Alzheimer’s Disease treatment.
  • The leading Dementia Associated With Alzheimer’s Disease Companies such as BioVie, Karuna Therapeutics, Cassava Sciences, Inc., Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd and others.
  • Promising Dementia Associated With Alzheimer’s Disease Pipeline Therapies such as ITI-1284, Brexpiprazole, KarXT, Quetiapine Fumarate, DMB-I (Dimebon), Rifaximin SSD 40 mg IR tablet, OPC-34712, and others.

Stay informed about the cutting-edge advancements in Dementia Associated With Alzheimer’s Disease treatments. Download for updates and be a part of the revolution in care @ Dementia Associated With Alzheimer’s Disease Clinical Trials Assessment

Dementia Associated With Alzheimer’s Disease Emerging Drugs Profile

  • NE3107: BioVie

NE3107 is an orally available small molecule with potential anti-inflammatory and insulin-sensitizing properties that can cross the blood-brain barrier. It was originally developed by NeurMedix and acquired by BioVie in April. The experimental molecule works by blocking the activation of two major regulators of inflammatory pathways: extracellular signal regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). NFκB is activated by amyloid beta and tau — two proteins that form toxic clumps that contribute to Alzheimer’s — and by the pro-inflammatory molecules that it stimulates, leading to chronic inflammation. NE3107 was found to have no immunosuppressive effects and to block ERK- and NF-κB-induced inflammation without suppressing their functions involved in maintaining overall balance, such as insulin signaling and nerve cell growth and survival. Currently, the drug is in Phase III stage of development for the treatment of Alzheimer Disease.

  • KarXT: Karuna Therapeutics

KarXT, a combination of xanomeline and trospium, is an investigational treatment developed by Karuna Therapeutics, primarily aimed at addressing psychosis associated with Alzheimer’s disease (AD) and schizophrenia. KarXT functions as a muscarinic receptor agonist, specifically targeting the M1 and M4 muscarinic acetylcholine receptors. Xanomeline activates these receptors, which are crucial for cognitive processes such as learning and memory. Trospium, on the other hand, is included to mitigate peripheral side effects associated with xanomeline, such as nausea and vomiting, by preventing its action on muscarinic receptors outside the brain. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Dementia Associated With Alzheimer’s Disease.

  • Simufilam: Cassava Sciences

Simufilam (formerly known as PTI-125) is an investigational drug being developed by Cassava Sciences. It targets an altered form of filamin A (FLNA), a protein implicated in the disease’s pathology. Unlike traditional Alzheimer’s treatments that focus on clearing amyloid plaques, simufilam works by stabilizing FLNA, thereby potentially reducing neuroinflammation and cognitive decline associated with the disease. Currently, the drug is in the Phase III stage of development to treat Dementia Associated With Alzheimer’s Disease.

  • CT-1812: Cognition Therapeutics

Cognition Therapeutics isdeveloping CT1812, an oral, brain-penetrant, small molecule therapeutic, which has been shown to protect neurons and synapses by preventing the binding of toxic oligomers. CT1812 acts as a neuroprotective agent both by shielding neurons and synapses from oligomer binding and by preventing oligomers from attaching to synapses in the first place. CT1812 may help mitigate the neurotoxic effects, slowing cognitive decline and progression of Alzheimer’s disease. Currently, the drug is in the Phase II stage of development to treat Alzheimer’s-disease.

  • CM383: KeyMed Biosciences

CM383 is an investigational drug being developed for the treatment of Alzheimer’s disease. It is a small molecule designed to target the underlying mechanisms of the disease, specifically by modulating the immune response and reducing neuroinflammation, which are key factors in Alzheimer’s pathology. CM383 works by targeting the immune system’s response to amyloid-beta plaques, which are characteristic of Alzheimer’s disease. It aims to enhance the brain’s ability to clear these plaques and improve neuronal health. This approach is distinct from many traditional Alzheimer’s treatments that primarily focus on amyloid plaque reduction or cholinergic modulation. Currently, the drug is in the Phase I stage of development to treat Alzheimer’s-disease.

The Dementia Associated With Alzheimer’s Disease Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Dementia Associated With Alzheimer’s Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dementia Associated With Alzheimer’s Disease Treatment.
  • Dementia Associated With Alzheimer’s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Dementia Associated With Alzheimer’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dementia Associated With Alzheimer’s Disease market

Learn more about Dementia Associated With Alzheimer’s Disease Drugs opportunities in our groundbreaking Dementia Associated With Alzheimer’s Disease Research and development projects @ Dementia Associated With Alzheimer’s Disease Unmet Needs

Dementia Associated With Alzheimer’s Disease Companies

BioVie, Karuna Therapeutics, Cassava Sciences, Inc., Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd and others.

Dementia Associated With Alzheimer’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Dementia Associated With Alzheimer’s Disease Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in Dementia Associated With Alzheimer’s Disease treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Dementia Associated With Alzheimer’s Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Dementia Associated With Alzheimer’s Disease Pipeline Report

  • Coverage- Global
  • Dementia Associated With Alzheimer’s Disease Companies- BioVie, Karuna Therapeutics, Cassava Sciences, Inc., Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd and others.
  • Dementia Associated With Alzheimer’s Disease Pipeline Therapies- ITI-1284, Brexpiprazole, KarXT, Quetiapine Fumarate, DMB-I (Dimebon), Rifaximin SSD 40 mg IR tablet, OPC-34712, and others.
  • Dementia Associated With Alzheimer’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Dementia Associated With Alzheimer’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Dementia Associated With Alzheimer’s Disease Pipeline on our website @ Dementia Associated With Alzheimer’s Disease Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Dementia Associated With Alzheimer’s Disease Executive Summary
  3. Dementia Associated With Alzheimer’s Disease Overview
  4. Dementia Associated With Alzheimer’s Disease Pipeline Therapeutics
  5. Dementia Associated With Alzheimer’s Disease Therapeutic Assessment
  6. Dementia Associated With Alzheimer’s Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. NE3107: BioVie
  9. Mid Stage Products (Phase II)
  10. CT-1812: Cognition Therapeutics
  11. Early Stage Products (Phase I)
  12. CM383: KeyMed Biosciences
  13. Preclinical and Discovery Stage Products
  14. Drug name: Company name
  15. Inactive Products
  16. Dementia Associated With Alzheimer’s Disease Key Companies
  17. Dementia Associated With Alzheimer’s Disease Key Products
  18. Dementia Associated With Alzheimer’s Disease- Unmet Needs
  19. Dementia Associated With Alzheimer’s Disease- Market Drivers and Barriers
  20. Dementia Associated With Alzheimer’s Disease- Future Perspectives and Conclusion
  21. Dementia Associated With Alzheimer’s Disease Analyst Views
  22. Dementia Associated With Alzheimer’s Disease Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dementia Associated With Alzheimer’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Acute Lymphocytic Leukemia Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Acute Lymphocytic Leukemia Pipeline Insight 2025” report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Acute Lymphocytic Leukemia pipeline landscape. It covers the Acute Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Acute Lymphocytic Leukemia Research. Learn more about our innovative pipeline today! @ Acute Lymphocytic Leukemia Pipeline Outlook

Key Takeaways from the Acute Lymphocytic Leukemia Pipeline Report

  • In March 2025, Janssen Research & Development, LLC conducted a study is to evaluate the efficacy of daratumumab in addition to standard chemotherapy in pediatric participants with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL) and T-cell ALL/LL as measured by the complete response (CR) rate.
  • In March 2025, Pfizer organized a phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and
  • In March 2025, Amgen announced a phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics (PK) of Blinatumomab in Chinese Pediatric Subjects With Relapsed or Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL).
  • In March 2025, AbbVie organized an extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
  • DelveInsight’s Acute Lymphocytic Leukemia pipeline report depicts a robust space with 125+ active players working to develop 130+ pipeline therapies for Acute Lymphocytic Leukemia treatment.
  • The leading Acute Lymphocytic Leukemia Companies such as Orca Biosystems, Inc, Jazz Pharmaceuticals, Shenzhen TargetRx, Inc, Cellectis, ADC Therapeutics S.A., Kunming Hope of Health Hospital, Beam Therapeutics Inc., Shenzhen BinDeBio Ltd., Kite, A Gilead Company, Sumitomo Pharma America, Inc., In8bio Inc., Fate Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd., Janssen Research & Development, LLC, Medolution Ltd., Kymera Therapeutics, Inc., Kite, A Gilead Company | Gilead Sciences, Newave Pharmaceutical Inc, Servier, Meryx, Inc., Armaceutica, Inc., Hangzhou Qihan Biotech Co., Ltd., Nanjing Bioheng Biotech, Sanofi, Syndax Pharmaceuticals, Vincerx Pharma, Inc. and others.
  • Promising Acute Lymphocytic Leukemia Pipeline Therapies such as Omitted Doxorubicin, Blinatumomab, Dexamethasone, Vincrisitne, Recombinant Asparaginase, Inotuzumab Ozogamicin and others.

Stay informed about the cutting-edge advancements in Acute Lymphocytic Leukemia treatments. Download for updates and be a part of the revolution in care @ Acute Lymphocytic Leukemia Clinical Trials Assessment

Acute Lymphocytic Leukemia Emerging Drugs Profile

  • Orca-T: Orca Biosystems, Inc.

Orca-T is an investigational high-precision cell therapy designed to replace a patient’s cancerous blood and immune system with a healthy one while dramatically lowering their risk of developing GvHD and other potentially life-threatening side effects. In the Phase Ib/II study, when measured against a concurrent, nonrandomized single-center comparator for allogeneic transplant patients, Orca-T demonstrated preliminary evidence of significantly higher GvHD-free, relapse-free survival rates after 1 year, improved relapse-free survival rates and lower rates of chronic GvHD. Currently, the drug is in Phase III stage of its development for the treatment of ALL.

  • TGRX-814: Shenzhen TargetRx, Inc.

TGRX-814 is a highly selective inhibitor of the BCL2 (over BCL-XL) for the treatment of CLL with or without the del(17p)/TP53 mutation, NHL, SLL, DLBL, MM, etc. Notably, TGRX-814 has an excellent selectivity profile for BCL-XL. TGRX-814 is modified and optimized through classical bioisosterism and molecule simulation technologies. In-vitro and in-vivo assays have shown that TGRX-814 improves oral metabolism, increases in vivo exposure, and reduces compound clearance while maintaining in vitro and in vivo bioactivity. Moreover, TGRX-814 obtained over 2-fold increase in bioavailability compared to the marketed drug Venetoclax, resulting in a significant increase in efficacy. Currently, the drug is in Phase I/II stage of its development for the treatment of ALL.

  • UCART22: Cellectis

UCART22 is one of Cellectis’ wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Like CD19, CD22 is a cell surface antigen expressed from the pre-B-cell stage of development through mature B-cells. CD22 expression occurs in more than 90% of patients with B-ALL. It is currently in phase I stage of development. Currently, the drug is in Phase I stage of its development for the treatment of ALL.

The Acute Lymphocytic Leukemia Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Acute Lymphocytic Leukemia with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Lymphocytic Leukemia Treatment.
  • Acute Lymphocytic Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Acute Lymphocytic Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Lymphocytic Leukemia market

Learn more about Acute Lymphocytic Leukemia Drugs opportunities in our groundbreaking Colo Acute Lymphocytic Leukemia Research and development projects @ Acute Lymphocytic Leukemia Unmet Needs

Acute Lymphocytic Leukemia Companies

Orca Biosystems, Inc, Jazz Pharmaceuticals, Shenzhen TargetRx, Inc, Cellectis, ADC Therapeutics S.A., Kunming Hope of Health Hospital, Beam Therapeutics Inc., Shenzhen BinDeBio Ltd., Kite, A Gilead Company, Sumitomo Pharma America, Inc., In8bio Inc., Fate Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd., Janssen Research & Development, LLC, Medolution Ltd., Kymera Therapeutics, Inc., Kite, A Gilead Company | Gilead Sciences, Newave Pharmaceutical Inc, Servier, Meryx, Inc., Armaceutica, Inc., Hangzhou Qihan Biotech Co., Ltd., Nanjing Bioheng Biotech, Sanofi, Syndax Pharmaceuticals, Vincerx Pharma, Inc. and others.

Acute Lymphocytic Leukemia (ALL) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Acute Lymphocytic Leukemia Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in Acute Lymphocytic Leukemia Treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Acute Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspectives

Scope of the Acute Lymphocytic Leukemia Pipeline Report

  • Coverage- Global
  • Acute Lymphocytic Leukemia Companies- Orca Biosystems, Inc, Jazz Pharmaceuticals, Shenzhen TargetRx, Inc, Cellectis, ADC Therapeutics S.A., Kunming Hope of Health Hospital, Beam Therapeutics Inc., Shenzhen BinDeBio Ltd., Kite, A Gilead Company, Sumitomo Pharma America, Inc., In8bio Inc., Fate Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd., Janssen Research & Development, LLC, Medolution Ltd., Kymera Therapeutics, Inc., Kite, A Gilead Company | Gilead Sciences, Newave Pharmaceutical Inc, Servier, Meryx, Inc., Armaceutica, Inc., Hangzhou Qihan Biotech Co., Ltd., Nanjing Bioheng Biotech, Sanofi, Syndax Pharmaceuticals, Vincerx Pharma, Inc. and others.
  • Acute Lymphocytic Leukemia Pipeline Therapies- Omitted Doxorubicin, Blinatumomab, Dexamethasone, Vincrisitne, Recombinant Asparaginase, Inotuzumab Ozogamicin and others.
  • Acute Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Acute Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Acute Lymphocytic Leukemia Pipeline on our website @ Acute Lymphocytic Leukemia Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Acute-Lymphocytic-Leukemia: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Acute-Lymphocytic-Leukemia– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Orca-T: Orca Biosystems, Inc.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Product Name: Company Name
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. TGRX-814: Shenzhen TargetRx, Inc.
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Acute-Lymphocytic-Leukemia Key Companies
  21. Acute-Lymphocytic-Leukemia Key Products
  22. Acute-Lymphocytic-Leukemia- Unmet Needs
  23. Acute-Lymphocytic-Leukemia- Market Drivers and Barriers
  24. Acute-Lymphocytic-Leukemia- Future Perspectives and Conclusion
  25. Acute-Lymphocytic-Leukemia Analyst Views
  26. Acute-Lymphocytic-Leukemia Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Lymphocytic Leukemia Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Colorectal Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and 200+ pipeline drugs in Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Colorectal Cancer Research. Learn more about our innovative pipeline today! @ Colorectal Cancer Pipeline Outlook

Key Takeaways from the Colorectal Cancer Pipeline Report

  • In March 2025, HiberCell, Inc. announced a study of phase 1b, safety, pharmacokinetic, and efficacy, multicenter, dose-escalating Study of Imprime PGG™ Injection dosed in combination with Cetuximab and concomitant irinotecan therapy. Enrolled patients will have a confirmed diagnosis of recurrent or progressive colorectal carcinoma following treatment with a 5-fluorouracil-containing regimen.
  • In March 2025, Bristol-Myers Squibb organized a study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
  • In March 2025, Seagen conducted a study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
  • In March 2025, Janssen Research & Development, LLC announced a study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.
  • DelveInsight’s Colorectal Cancer pipeline report depicts a robust space with 195+ active players working to develop 200+ pipeline therapies for Acute Lymphocytic Leukemia treatment.
  • The leading Colorectal Cancer Companies such as Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
  • Promising Colorectal Cancer Therapies such as Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEPI1018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitixorin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811, EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAd703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-8444, RGX-202-01, NE-201, DS-8201, GCC19CART, M 9140, LYL845, and others.

Stay informed about the cutting-edge advancements in Colorectal Cancer treatments. Download for updates and be a part of the revolution in care @ Colorectal Cancer Clinical Trials Assessment

Colorectal Cancer Emerging Drugs Profile

  • XL092 : Exelixis

XL092 is an investigational small molecule, oral tyrosine kinase inhibitors (TKI) that inhibits the activity of receptor tyrosine kinases involved in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes like oncogenesis, metastasis, and tumor angiogenesis. Currently it is in Phase III stage of clinical trial evaluation to treat Colorectal Cancer.

  • Adagrasb : Mirati Therapeutics

Adagrasib is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition, an attribute that could be important to treat KRASG12C-mutated cancers. The drug candidate is being evaluated as monotherapy and in combination with other anti-cancer therapies in patients with advanced KRASG12C-mutated colorectal cancer. Currently being evaluated in the Phase III studies.

  • Olaparib : Merck Sharp & Dohme LLC/Astrazeneca

Olaparib is an investigational is a first-in-class Poly (ADP-ribose) polymerase PARP inhibitors and the first targeted treatment that potentially exploit DNA damage response (DDR) pathway deficiencies, like BRCA mutations, to preferentially kill cancer cells. Olaparib is being jointly developed and commercialized by AstraZeneca and Merck. Currently the drug is being evaluated in Phase III for the treatment of Colorectal Cancer.

  • DS-8201: Daiichi Sankyo

DS-8201 a proprietary antibody-drug conjugate (ADC) is a smart chemotherapy comprised of a humanized HER2 antibody attached to a novel topoisomerase I inhibitor payload by a tetra peptide-based linker. It is designed to target and deliver chemotherapy inside cancer cells and reduce systemic exposure to the cytotoxic payload (or chemotherapy) compared to the way chemotherapy is commonly delivered. The drug is been developed in collaboration with AstraZeneca. The drug is in Phase II stage of clinical trials.

  • Ompenaclid: Inspirna

Ompenaclid is a first in class oral small molecule inhibitor of the creatine transport channel SLC6A8 a novel target that is enriched under hypoxic conditions and provides tumor cells with an additional energy source. Ompenaclid triggers tumor regressions in CRC patients by inducing apoptosis of tumor cells. It is based on Rgenix technology. The drug is in Phase II stage of clinical trials.

  • LYL845: Lyell Immunopharma

LYL845, an autologous tumor-infiltrating lymphocytes (TIL). It is administered through the intravenous route. It is being developed based on an ex vivo epigenetic reprogramming (Epi-R) technology platform is currently being investigated in a Phase 1 clinical trial in patients suffering with relapsed or refractory metastatic colorectal cancer.

  • RG6286: Genentech

RG6286 (BLYG-8824A) is under development for the treatment of relapsed or refractory, advanced, or metastatic colorectal cancer. It is new chemical entity, administered through an intravenous route currently being investigated in a Phase 1 clinical trial.

The Colorectal Cancer Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Colorectal Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Colorectal Cancer Treatment.
  • Colorectal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Colorectal Cancer market

Learn more about Colorectal Cancer Drugs opportunities in our groundbreaking Colorectal Cancer Research and development projects @ Colorectal Cancer Unmet Needs

Colorectal Cancer Companies

Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE and others.

Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Colorectal Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in Colorectal Cancer treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Colorectal Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Colorectal Cancer Pipeline Report

  • Coverage- Global
  • Colorectal Cancer Companies- Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
  • Colorectal Cancer Therapies- Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEPI1018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitixorin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811, EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAd703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-8444, RGX-202-01, NE-201, DS-8201, GCC19CART, M 9140, LYL845, and others.
  • Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Colorectal Cancer Pipeline on our website @ Colorectal Cancer Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Colorectal Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Comparative Analysis
  8. XL092: Exelixis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Early Stage Products (Phase I)
  12. LYL845: Lyell Immunopharma
  13. Inactive Products
  14. Colorectal Cancer Key Companies
  15. Colorectal Cancer Key Products
  16. Colorectal Cancer – Unmet Needs
  17. Colorectal Cancer – Market Drivers and Barriers
  18. Colorectal Cancer – Future Perspectives and Conclusion
  19. Colorectal Cancer Analyst Views
  20. Colorectal Cancer Key Companies
  21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Colorectal Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies